Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Steven Richard Witowski"'
Autor:
Prasoon Chaturvedi, Erica Evans, Russell Karp, Matthew T. Labenski, Heather Lounsbury, Martin I. Freed, Steven Richard Witowski, Hormoz Mazdiyasni, Richland Wayne Tester, M. Nacht, Sharon Aslanian, Michael Sheets, Russell C. Petter, Juswinder Singh, Zhendong Zhu, Alex Dubrovskiy, William F. Westlin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 346:219-228
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies. Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61db1f19445091f3dba37c82d79cc38
https://doi.org/10.1124/jpet.113.203489
https://doi.org/10.1124/jpet.113.203489
Autor:
Jeff Porter Sharman, Wael A. Harb, James M. Foran, Daruka Mahadevan, Thomas J. Kipps, Bruce A. Silver, Susan O'Brien, Paul M. Barr, Jennifer R. Brown, Kathryn Stiede, Erica Evans, Kevin R. Kelly, John Sweetenham, Shuo Ma, Juswinder Singh, Marshall T. Schreeder, Heather Lounsbury, Janice Gabrilove, William F. Westlin, Steven Richard Witowski
Publikováno v:
Journal of Clinical Oncology. 30:8032-8032
8032 Background: Btk supports activation, survival, and proliferation of malignant B cells in CLL and B-NHL. AVL-292 is an oral, potent (IC50 < 0.5nM), selective small molecule covalent inhibitor of Btk. Methods: Patients (pts) with previously treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b38294c113fbbdf2b983473634a97d0d
https://doi.org/10.1200/jco.2012.30.15_suppl.8032
https://doi.org/10.1200/jco.2012.30.15_suppl.8032